Item 5.02. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
OnFebruary 10, 2021 , the Board of Directors (the "Board") ofJounce Therapeutics, Inc. (the "Company"), appointedLuisa Salter-Cid , Ph.D. as a director and as a member of the Science and Technology committee of the Board, effective immediately.Dr. Salter-Cid has been designated as a Class I director to serve in accordance with the Company's Amended and Restated By-Laws until the Company's 2021 Annual Meeting of Stockholders or until her successor has been duly elected and qualified, or until her earlier death, removal or resignation.Dr. Salter-Cid has served as the Chief Scientific Officer of Gossamer Bio, Inc. ("Gossamer"), a publicly-traded clinical-stage biopharmaceutical company, sinceAugust 2018 . Prior to joining Gossamer,Dr. Salter-Cid worked at Bristol-Myers Squibb in increasing positions of responsibility from 2005 toAugust 2018 , most recently as Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery where she focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. She was a member of theScientific Advisory Board of Enterome SA untilJuly 2018 .Dr. Salter-Cid holds a B.S. in Biology fromUniversity of Lisbon , an M.S. in Biology fromFlorida International University and a Ph.D. in Immunology from theUniversity of Miami School of Medicine . In accordance with the Company's non-employee director compensation policy,Dr. Salter-Cid will receive annual cash compensation of$35,000 as a member of the Board and$6,000 as a member of the Science and Technology committee of the Board, as well as reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and committees thereof. She was granted an option to purchase 31,400 shares of the Company's common stock, par value$0.001 per share, with an exercise price equal to the closing price of the Company's common stock on the Nasdaq Global Select Market on the date of her appointment, which option will vest in equal quarterly installments during the twelve quarters following the grant date, subject toDr. Salter-Cid's continued service on the Board.Dr. Salter-Cid also will enter into a standard form of indemnification agreement with the Company, in the form that is filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 (File No. 333-215372), filed with theSecurities and Exchange Commission onDecember 30, 2016 . There are no arrangements or understandings betweenDr. Salter-Cid and any other person pursuant to whichDr. Salter-Cid was elected as a director. There are no transactions in whichDr. Salter-Cid has an interest requiring disclosure under Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source